You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Shanghai, China
    Zhongshan hospital, Fudan University
Aug 12, 2023

Profiling of Circulating Immune Cells to Uncover Response

Not yet recruiting
  • Melanoma
    • (no location specified)
    Nov 23, 2023

    Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

    Not yet recruiting
    • Lung Cancer
    • Centipeda minima+PD-1/PD-L1 inhibitor
    • PD-1/PD-L1 inhibitor
    • (no location specified)
    Feb 17, 2023

    Fruquintinib With PD-1 Inhibitors Versus TAS-102 With

    Completed
    • Metastatic Colorectal Adenocarcinoma
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Sep 2, 2023

    Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)

    Not yet recruiting
    • Esophageal Squamous Carcinoma
    • HER-2 Protein Overexpression
    • (no location specified)
    Sep 24, 2023

    Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Oligometastatic Disease
    • PD-1 combined with SBRT
    • Guangzhou, Guangdong, China
      Mian Xi
    Dec 18, 2022

    NSCLC Trial in Zhengzhou (L-TIL, Tislelizumab, Docetaxel)

    Recruiting
    • Non-small Cell Lung Cancer
    • L-TIL, Tislelizumab, Docetaxel
    • Zhengzhou, Henan, China
      No.127 Dongming Road
    May 17, 2023

    Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays

    Not yet recruiting
    • Lung Neoplasm
    • +2 more
    • Tumor samples
    • Bordeaux, France
      CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médic
    Aug 28, 2023

    Colorectal Liver Metastases Trial in Nanjing (Radiation: High- and Low-dose radiotherapy, PD-1 Inhibitors)

    Recruiting
    • Colorectal Liver Metastases
    • Radiation: High- and Low-dose radiotherapy
    • PD-1 Inhibitors
    • Nanjing, Jiangsu, China
      Jiangsu Cancer Hospital
    Sep 13, 2023

    Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

    Completed
    • Colorectal Cancer
    • Fruquintinib combined with anti-PD-1 antibodies
    • ChangSha, Hunan, China
      Hunan Cancer Hospital
    Aug 27, 2023

    Leptomeningeal Disease Trial in Germany (Nivolumab [Opdivo])

    Recruiting
    • Leptomeningeal Disease
    • Nivolumab [Opdivo]
    • Freiburg, Germany
    • +6 more
    Nov 2, 2022

    Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

    Not yet recruiting
    • Advanced Non Small Cell Lung Cancer
    • (no location specified)
    Oct 24, 2023

    Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

    Not yet recruiting
    • Multiple Cancer
    • Colorectal Cancer
    • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
    • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
    • (no location specified)
    Aug 20, 2023

    Immunotherapy, ADR Trial in Beijing

    Not yet recruiting
    • Immunotherapy
    • ADR
      • Beijing, Beijing, China
        Xuanwu Hospital
      Jan 27, 2023

      Esophageal Squamous Cell Carcinoma Abdominal Stage 0 Trial in Guangzhou (PD-1 Inhibitors, Irinotecan, Capecitabine tablets)

      Recruiting
      • Esophageal Squamous Cell Carcinoma Abdominal Stage 0
      • PD-1 Inhibitors
      • +2 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Feb 20, 2023

      Sarcoma Trial in Shanghai (MASCT-I,PD1 Antibody,Apatinib)

      Active, not recruiting
      • Sarcoma
      • MASCT-I,PD1 Antibody,Apatinib
      • Shanghai, Shanghai, China
        Shanghai Sixth People's Hospital
      Nov 22, 2022

      Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

      Recruiting
      • Nasopharyngeal Carcinoma
      • Anti-EGFR and PD-1 inhibitor arm
      • Shanghai, Shanghai, China
        Eye & ENT Hospital of Fudan University
      Nov 26, 2023

      Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)

      Not yet recruiting
      • Rectal Cancer
      • Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
      • (no location specified)
      Aug 29, 2023

      Malignant Melanomas Trial in Fuzhou (Recombinant Human Adenovirus Type 5 Injection)

      Enrolling by invitation
      • Malignant Melanomas
      • Recombinant Human Adenovirus Type 5 Injection
      • Fuzhou, Fujian, China
        Fujian Cancer Hospital, Department of Internal Medicine, Ward 19
      Jul 7, 2023

      Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

      Completed
      • Metastatic Colorectal Adenocarcinoma
      • regorafenib plus anti-PD-1 antibodies
      • Changsha, Hunan, China
        Hunan Cancer hospital
      Jul 4, 2023

      Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1

      Active, not recruiting
      • Gastric or Gastroesophageal Junction Adenocarcinoma
      • neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
      • Nanjing, Jiangsu, China
        Jiangsu Cancer Hospital
      Jul 4, 2023

      Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

      Recruiting
      • Digestive System Cancers
      • Beijing, China
        Peking University Cancer Hospital
      Oct 25, 2023

      B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

      Active, not recruiting
      • B-cell Lymphoma
      • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
      • Hangzhou, Zhejiang, China
        The First Affiliated Hospital, Zhejiang University School of Med
      Sep 28, 2022

      Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Tumors Trial in Guangzhou (Pemigatinib, PD-1 Inhibitors)

      Recruiting
      • Carcinoma
      • +4 more
      • Guangzhou, Guangdong, China
        Lei Zhang
      Jun 21, 2023

      Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

      Recruiting
      • Hepatocellular Carcinoma
      • Shanghai, China
        Zhongshan Hospital Fudan university
      Jan 31, 2023